ATHX earnings

Athersys, Inc. (NASDAQ:ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today it will host a business update conference call on August 9, 2023, at 4:30 p.m. Eastern Time. Dan Camardo, Chief Executive Officer, Maia Hansen, Chief Operating Officer, Kasey Rosado, Interim Chief Financial Officer, and Willie Mays, Executive Vice President of Regenerative Medicine and Head of Neuroscience, will provide an overview of the Company's recent clinical and operational progress and discuss timing to conduct an interim analysis with MASTERS-2, a Phase 3 pivotal trial of MultiStem treatment in ischemic stroke. Date

Athersys, Inc. (NASDAQ:ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today it will host a business update conference call on April 20, 2023 at 11:00 a.m. Eastern Time. Dan Camardo, Chief Executive Officer, Maia Hansen, Chief Operating Officer, Kasey Rosado, Interim Chief Financial Officer, and Willie Mays, Executive Vice President of Regenerative Medicine and Head of Neuroscience, will provide an overview of the Company's recent clinical and operational progress and discuss upcoming milestones supporting the pivotal Phase 3 ischemic stroke trial, MASTERS-2. Date April 20, 2023 Time

Athersys, Inc. (NASDAQ:ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today it will host a business update conference call on February 14, 2023 at 11:00 a.m. Eastern Time. Dan Camardo, Chief Executive Officer, Maia Hansen, Chief Operating Officer, Kasey Rosado, Interim Chief Financial Officer, and Robert "Willie" Mays, Executive Vice President Regenerative Medicine and Head of Neuroscience, will provide an overview of the Company's recent clinical and operational progress, upcoming milestones and vision for the year. Date February 14, 2023 Time 11:00 a.m. (Eastern Time) Live webcast re

Athersys, Inc. (NASDAQ:ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today that it intends to file its quarterly report on Form 10-Q for the three months ended September 30, 2022 with the U.S. Securities and Exchange Commission (SEC) after market close on Monday, November 14, 2022, issue a news release reporting those financial results and recent business highlights before market open on Tuesday, November 15, 2022, and hold a conference call at 11:00 a.m. Eastern Time on Tuesday, November 15, 2022. The company is rescheduling the reporting of its third quarter 2022 financial results in order to provide sufficient time

Athersys, Inc. (NASDAQ:ATHX) will be hosting a conference call on Thursday, November 10, 2022, at 4:30 PM Eastern Time to review its third quarter 2022 financial results. Members of the management team will host the call as follows: Date November 10, 2022 Time 4:30 p.m. (Eastern Time) Live webcast registration Webcast link Phone registration Call registration link We encourage shareholders to register and listen to the call using the webcast link above. Once registered, you will receive an email containing the toll-free number, a direct entry passcode and a registrant ID. Please send questions you would like management to address in advance of the call to

Athersys, Inc. (NASDAQ:ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today it will host a business update conference call on October 6, 2022 at 4:00 pm Eastern Time. Dan Camardo, Chief Executive Officer, Maia Hansen, Chief Operating Officer, Kasey Rosado, Interim Chief Financial Officer, and Robert "Willie" Mays, Executive Vice President Regenerative Medicine and Head of Neuroscience, will provide an overview of the company's accomplishments since its recently announced restructuring. Date October 6, 2022 Time 4:00 p.m. (Eastern Time) Live webcast registration Webcast link Phone registration

Corporate restructuring underway and MASTERS-2 clinical trial prioritized Conference call begins at 4:30 p.m. Eastern time today Athersys, Inc. (NASDAQ:ATHX) announced today its financial results for the three and six months ended June 30, 2022 and provided a business update. Second quarter 2022 Corporate and Operational Highlights: Corporate Restructuring Implemented a restructuring of our organization with the intention of significantly reducing expenses, conserving cash, improving focus of the Company's activities and becoming more attractive to potential financial and strategic partners. Reduction in workforce of up to 70% including changes to leadership team Reduced size of B

Athersys, Inc. (NASDAQ:ATHX) will release its second quarter 2022 financial results at approximately 4:00 PM Eastern Time on Thursday, August 11, 2022, and will host a conference call shortly thereafter at 4:30 PM Eastern Time to review the results. Members of the management team will host the call as follows: Date August 11, 2022 Time 4:30 p.m. (Eastern Time) Live webcast registration Webcast link Phone registration Call registration link We encourage shareholders to listen using the webcast link above. If you would like to dial in using the phone to ask a question, please register for the conference call ahead of time using the call registration link abo

Workforce reduction up to 70% Conference call today at 5:00 p.m. ET Athersys, Inc. (NASDAQ:ATHX) today announced a corporate restructuring plan to reduce costs and prioritize its lead clinical programs. In connection with the restructuring, the Company is reducing its workforce up to 70%, with the majority of the reduction expected to be completed by the end of June 2022. Reducing the workforce is an initial step the Company is taking to reduce its cost structure and become more attractive to both financial and strategic partners. As part of the restructuring plan, the Company also announced changes to its executive team. Mr. William (B.J.) Lehmann, President and Chief Operating Officer,

TREASURE topline results show evidence of therapeutic impact Study preliminary results analyses indicate good potential for favorable results in Athersys' MASTERS-2 study Conference call today at 8:30 a.m. ET Athersys, Inc. (NASDAQ:ATHX) announced today that its partner, HEALIOS K.K. (Healios), has reported topline results for its Japan ischemic stroke study, TREASURE. The randomized, double-blind placebo-controlled study included patients with moderate to moderate-severe ischemic stroke (baseline NIHSS 8-20) with administration of a single dose of MultiStem® cells (invimestrocel) or placebo by intravenous infusion within 18-36 hours of the event. The trial enrolled 206 patients and was

Management to host conference call following announcement of Phase 2/3 TREASURE data in May Athersys, Inc. (NASDAQ:ATHX) announced today its financial results for the three months ended March 31, 2022. In anticipation of the announcement in May of topline data from Athersys' partner, HEALIOS K.K. (Healios), for its Phase 2/3 TREASURE study evaluating MultiStem® (invimestrocel, HLCM051) for the treatment of ischemic stroke, Athersys will host its next investor conference call after the data are released. Athersys will share the conference call details in its news release reporting the data. "Since joining the Company in February, I've immersed myself in all aspects of the business to gain

Quarterly Conference Call to be Held Following Announcement of Phase 2/3 TREASURE Data in May Athersys, Inc. (NASDAQ:ATHX) today announced that it will release its first quarter 2022 financial results on Friday, May 6, 2022, at 8:00 a.m. EDT. In anticipation of the announcement of topline data from Athersys' partner, HEALIOS K.K., for its Phase 2/3 TREASURE study evaluating MultiStem® (invimestrocel, HLCM051) for the treatment of ischemic stroke in May, Athersys will host its next investor conference call after the data are released. Athersys will share the call details in its own news release reporting the data. About Athersys Athersys is a biotechnology company engaged in the discovery

Management to host conference call at 4:30 pm ET today; Dan Camardo, newly appointed Chief Executive Officer, will lead the call and share his initial perspective on the path to commercial success for the Company Athersys, Inc. (NASDAQ:ATHX) announced today its financial results for the three months and full year ended December 31, 2021, along with a corporate update. Daniel A. Camardo, Athersys' new Chief Executive Officer as of February 14, 2022, commented, "I'm excited to be leading Athersys at such a pivotal time as I believe we have the potential to be a global leader in cell therapy and regenerative medicine and effectively treat various diseases with significant unmet medical need

New CEO, Daniel A. Camardo, and Management to Host Conference Call on March 15, 2022 Athersys, Inc. (NASDAQ:ATHX) will release its fourth quarter and full year 2021 financial results on Tuesday, March 15, 2022, after the close of the U.S. financial markets. Athersys' new CEO, Daniel A. Camardo, along with the Company's management team, will host a conference call at 4:30 p.m. Eastern Time that day to review the results. Mr. Camardo joined the company as CEO on February 14, 2022. Mr. Camardo comes to Athersys at a pivotal time to lead the Company's transition to a commercial biopharmaceutical company and leader in cell therapy. Dan has over 25 years of commercial leadership experience and w

Positive topline data for ARDS study and completion of enrollment in Japan ischemic stroke study are important milestones for development and potential commercialization of MultiStem® cell therapy Management to host conference call at 4:30 pm EST today Athersys, Inc. (NASDAQ:ATHX) announced today its financial results for the three months ended September 30, 2021 and provided a corporate update. "The third quarter brought several important milestones in the development and potential commercialization of MultiStem® cell therapy," stated Mr. William (B.J.) Lehmann, Jr., Interim Chief Executive Officer of Athersys. "First, our partner Healios announced positive topline data from its ONE-BRI

Athersys, Inc. (NASDAQ:ATHX) will release its third quarter 2021 financial results at approximately 4:00 PM Eastern Time on Monday, November 15, 2021, and will host a conference call shortly thereafter at 4:30 PM Eastern Time to review the results. Members of the management team will host the call as follows: Date November 15, 2021 Time 4:30 p.m. (Eastern Time) Live webcast registration Webcast link Phone registration Call registration link We encourage shareholders to listen using the webcast link above. If you would like to dial in using the phone to ask a question, please register for the conference call ahead of time using the call registration lin

Announced promising topline ARDS results reported by Athersys partner, HEALIOS K.K., from its ONE-BRIDGE study Advanced partnership with Healios to enhance commercial readiness preparations for MultiStem in Japan Made continued progress in establishing manufacturing and other capabilities for commercial success Management to host conference call at 4:30 pm EDT today Athersys, Inc. (NASDAQ:ATHX) announced today its financial results for the three months ended June 30, 2021 and provided a corporate update. "We are happy about the positive topline results for the ONE-BRIDGE ARDS study in Japan reported by Healios last week," stated Mr. William (B.J.) Lehmann, Jr., Interim Chief Executive